Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. Based on our deep expertise in endoplasmic reticulum (ER) stress biology and the tumor microenvironment, we are pioneering first-in-class ER stress response modulators to boost the immune system's ability to fight cancer. Our lead program is a first-in-class IRE1a inhibitor. We are pursuing multiple additional ER stress pathway targets in the tumor micro-environment, as well as in other diseases where ER stress plays an important role.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/28/18	$48,000,000	Series A	AbbVie Biotech Ventures Alexandria Real Estate Equities New York Ventures Polaris Partners Taiho Ventures Versant Ventures Yonghua Capital	undisclosed